How to Buy Eli Lilly & Co Stock
Eli Lilly & Co
Eli Lilly & Co is a general drug manufacturer company located in Indiana, United States, which is part of the Healthcare sector, and is traded under the ticker LLY on the NYSE exchange.
Eli Lilly & Co stock last closed at $1,076.48, up 0.47% from the previous day, and has increased 35.19% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.07 percentage points. Eli Lilly & Co stock is currently +72.57% from its 52-week low of $623.78, and -3.19% from its 52-week high of $1,111.99.
At the moment, there are 945.38M shares of LLY outstanding. The market cap of LLY is $1.02T. In the past 24 hours, 2.63M LLY shares were traded.
How to Buy Eli Lilly & Co Stock
Wondering how to invest in Eli Lilly & Co stock? Here's how.
- Figure out where to buy Eli Lilly & Co stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you choose where to buy Eli Lilly & Co stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Choose your payment method and add your info.
- Evaluate Eli Lilly & Co stock: The Eli Lilly & Co ticker symbol is LLY. Is Eli Lilly & Co stock a good investment? Should you buy shares of LLY? How do LLY's underlying business fundamentals look? Do top analysts think Eli Lilly & Co is a good buy? Why has LLY's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if LLY is a good stock to buy).
- Make your LLY buy order: Decide if you will purchase LLY shares at the current market price or use a limit order to buy LLY stock at a given price.
- Keep tabs on your LLY investment: Create a watchlist to get live updates on your investment in Eli Lilly & Co stock.
Step 1: Figure out where to buy Eli Lilly & Co stock
You will need a brokerage account in order to access the NYSE market and buy LLY stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you can invest in LLY today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create your new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on the best app for stock investing, you need to deposit funds:
Check out the video below for more details transferring money into your new investment account.
Step 4: Evaluate Eli Lilly & Co stock
After you have identified the best place to buy Eli Lilly & Co stock, it's important to research their stock before you invest, so you can wrap your head around the risk and opportunity.
Eli Lilly & Co Metrics
Fundamentals of LLY
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis.
You can see all of the due diligence checks on LLY's stock page.
Is LLY stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge LLY's true value.
Using relative valuations ratios:
- LLY could be overvalued based on its P/E ratio of 52.54x, relative to Drug Manufacturers - General industry P/E ratio of 46.08x
- LLY may be overvalued based on its P/B ratio of 42.77x, relative to Drug Manufacturers - General industry P/B ratio of 6.93x
- LLY could be overvalued based on its PEG ratio of 2.03x
You can do additional valuation analysis on LLY's stock here.
LLY Financial Health Overview
Positive Financial Indicators:
- LLY earnings of $22.50B is not sufficient to cover its interest payments.
- LLY's operating cash flow of $16.06B allows it to safely service it's debt of $42.51B.
- Total LLY debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the LLY balance sheet.
- There are more short-term assets than long-term liabilities on the LLY balance sheet.
- LLY profit margin has gone up from 20.5% to 31% in the past year.
Negative Financial Indicators:
- LLY has a relatively high debt to equity ratio of 3.83.
Do Wall Street analysts think it's a good time to buy LLY stock
Out of 16 Equities analysts who give recommendations on LLY, the consensus analyst rating on LLY is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent LLY Analyst Upgrades/Downgrades
Robyn Karnauskas, a bottom 16% analyst from Truist Securities maintains LLY with a strong buy rating and raises their LLY price target from $1,038.00 to $1,182.00, on Nov 19, 2025.
Truist Securities's Robyn Karnauskas raised their price target on Eli Lilly & Co (NYSE: LLY) by 13.9% from $1,038 to $1,182 on 2025/11/19. The analyst maintained their Strong Buy rating on the stock.
Karnauskas attributed their bullish stance on the stock to "the recently announced White House deal that provides reimbursement for weight loss medications to Medicare patients."
The analyst told readers to expect orforglipron to be available on the market in 1H 2026 and aruged that the competitive profiles of Zebpound and orforglipron will continue to support Eli Lilly's lead in the obesity space.
Chris Schott, a top 14% analyst from JP Morgan maintains LLY with a strong buy rating and raises their LLY price target from $1,050.00 to $1,150.00, on Nov 18, 2025.
Peter Verdult, a bottom 23% analyst from Citigroup maintains LLY with a strong buy rating and raises their LLY price target from $1,250.00 to $1,500.00, on Nov 12, 2025.
Ilya Zubkov, a bottom 44% analyst from Freedom Capital Markets downgrades LLY to a hold rating and raises their LLY price target from $750.00 to $950.00, on Nov 10, 2025.
David Risinger, a top 10% analyst from Leerink Partners upgrades LLY to a buy rating and raises their LLY price target from $886.00 to $1,104.00, on Nov 10, 2025.
You can dive deeper into what analysts are forecasting on the Eli Lilly & Co stock forecast page.
LLY Momentum
Is LLY Making Money?
Last year, LLY earnings were $18.41B. Over the past five year, LLY's earnings have grown by 27.21% per year. This was faster than the Drug Manufacturers - General industry average of 11.68%.
Last year, LLY revenue was $59.42B. During the past five year, LLY's revenue has gone up by 20.68% per year. This was faster than the Drug Manufacturers - General industry average of 10.99%.
Dig into LLY's earnings and revenue performance here.
Who is buying/selling LLY?
In the last 12 months, executives and large shareholders at LLY have sold more shares than they have bought.
Gabrielle Sulzberger, Director of LLY, was the latest LLY insider to buy. They bought $4,248.76 worth of LLY stock on Dec 15, 2025.
Research more about who owns LLY stock here.
Can I rely on LLY as an income stream?
Eli Lilly & Co pays a dividend of 0.42%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.76%. If you owned $1,000 of LLY stock, you would have been paid $4.18 in the past 12 months.
Eli Lilly & Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more data about Eli Lilly & Co dividend yield and history here.
What others are saying about LLY
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your LLY buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open Trade button and eToro will execute your order.
If you want additional help investing in stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your LLY investment
Now that you own some LLY shares, you'll want to keep up with your company.
Create a watchlist to see the latest developments about your LLY stock.
LLY Feed
How to Buy Stock in Eli Lilly & Co
To reiterate, here are the 6 steps you need to take to buy Eli Lilly & Co stock right now:
- Figure out where to buy Eli Lilly & Co stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Evaluate Eli Lilly & Co stock
- Make your LLY buy order
- Keep tabs on your LLY investment
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Eli Lilly & Co, add LLY to your watchlist by clicking the button below.
Other Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.